Organogenesis’s Merger with Avista Healthcare Public Acquisition Corp.

Foley Hoag LLP represented Organogenesis Inc., a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care, Surgical and Sports Medicine markets, in a definitive merger agreement with Avista Healthcare Public Acquisition Corp. (NASDAQ: AHPA ) (“AHPAC”), a publicly traded special purpose acquisition company.

Affiliates of Avista Capital Partners, a leading private equity firm, have agreed to invest $92 million in the combined company in conjunction with the transaction. Following the closing of the transaction, Organogenesis will be listed on the Nasdaq Stock Exchange under the ticker symbol “ORGO.” The combined company will have an anticipated initial enterprise value of approximately $673 million.

Foley Hoag partners William Kolb (Picture) and Stacie Aarestad and associates Ryan Rourke Reed, Remi Kathawa and Justin Beegle represented Organogenesis in the transaction.

Involved fees earner: William Kolb – Foley Hoag; Ryan M. Rourke Reed – Foley Hoag; Remi Kathawa – Foley Hoag; Justin Beegle – Foley Hoag; Stacie Aarestad – Foley Hoag;

Law Firms: Foley Hoag;

Clients: Organogenesis Inc.;

Author: Ambrogio Visconti